View in EDS HTML Full Text PDF Full Text

Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic.

Saved in:
Bibliographic Details
Title: Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic.
Authors: Kimura, Sakiko1 (AUTHOR) mochinag@cc.saga-u.ac.jp, Katsuya, Hiroo2 (AUTHOR), Nakashima, Chiho2 (AUTHOR), Sueoka-Aragane, Naoko2 (AUTHOR), Hayashida, Koji3 (AUTHOR), Sasaki, Kazumi4 (AUTHOR), Sogawa, Rintaro1 (AUTHOR), Furuno, Tatsuya1 (AUTHOR), Yamauchi, Moriyasu5 (AUTHOR), Sugiyama, Yoichiro5 (AUTHOR), Noshiro, Hirokazu6 (AUTHOR), Esaki, Motohiro7 (AUTHOR), Noguchi, Mitsuru8 (AUTHOR), Takahashi, Hirokazu9 (AUTHOR), Anzai, Keizo10 (AUTHOR), Yokoyama, Masatoshi11 (AUTHOR), Sugita, Kazunari12 (AUTHOR), Yamashita, Yoshio13 (AUTHOR), Kawaguchi, Atsushi14 (AUTHOR), Kimura, Shinya2 (AUTHOR)
Source: BMC Immunology. 4/16/2025, Vol. 26 Issue 1, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14712172
DOI:10.1186/s12865-025-00711-w